Orbit’s Peptide Display was conceived at the Weatherall Institute of Molecular Medicine in Oxford by Professors Ogg and Rabbitts. At that time (2014) there was a lack of technology to support the growing need to present and screen peptide libraries against live cells.

This new technology had all the positive attributes of phage display and in-vitro display methods whilst maintaining low background binding and excellent display density. In 2015, Orbit Discovery kicked off as a spin-out from Oxford University.


Our in vitro display technology uses small beads to link randomised peptide sequences to the DNA which encodes them. A DNA library is constructed which codes for a scaffold and the random or semi-randomised peptide sequence. Each piece of DNA in the library is attached to a bead so that each bead holds just one sequence.

In vitro transcription/translation results in a library of beads, each of which displays several thousand copies of its specific peptide.



The Orbit Peptide Display technology has the positive attributes of in vitro display, such as a cell-free environment and highly diverse libraries, combined with the sensitivity of in vivo methods.

Our technology allows for the introduction of non-natural amino acids into peptides and also the generation of cyclic, bicyclic and tricyclic peptides and the introduction of other constraints. Cyclic peptides are more stable and have potentially higher affinity and specificity compared to their linear counterparts. Further increases in stability and chemical diversity can be achieved by incorporation of methylated amino acids, D-amino acids and click chemistries that allow for post translational modifications.

Additionally, the Orbit technology is amenable to cell surface screening, enabling direct screening of cell surface target binding and subsequent functional cellular responses.